This study is a long-term post-treatment follow-up to study WV19432, which evaluated the
efficacy and safety of PEGASYS in patients with HBeAg positive chronic hepatitis B
(CHB).Patients who received treatment with PEGASYS, and completed follow-up, are eligible to
enter this post-treatment follow-up study. The anticipated time on study was 5 years, and the
target sample size is 100-500 individuals.